Testosterone Cypionate Erythrocytosis / Elevated Hematocrit: Severity Grading Rubric

Print or save as PDF

The 54% action threshold

A 2023 clinical consultation guide on managing erythrocytosis in men receiving testosterone therapy states that providers should decrease or discontinue therapy if the patient's hematocrit exceeds 54%, until the hematocrit normalizes [3]. That cutoff is an action level in the guide, not a symptom grade [3].

A 2022 review focused on testosterone therapy and secondary erythrocytosis argues that the hematocrit-based cutoffs present in multiple guidelines appear to be arbitrarily chosen, and that the evidence for harm from secondary polycythemia during therapy is scarce [7]. A 2025 systematic review of drug-induced erythrocytosis found no clear consensus among clinicians about how the condition should be diagnosed and managed [8].

What each hematocrit number means

• Above 50% before starting (2010 Endocrine Society guideline): recommends against starting testosterone therapy at this level [5]
• Above 50% (retrospective review of 178 hypogonadal men): the definition of erythrocytosis used; 66.7% of men on injectable testosterone met it [1]
• Above 52% (review of erythrocytosis in aging men): the definition used; men on testosterone had a 315% greater risk than controls [2]
• Above 54% (2023 clinical consultation guide): the level above which providers should decrease or discontinue until hematocrit normalizes [3]

Each line is a different group's cutoff, not a symptom tier.

How much does testosterone cypionate raise hematocrit?

A 2022 Bayesian network meta-analysis in the Journal of Urology pooled 29 placebo-controlled randomized trials covering 3,393 men. Intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% versus placebo (95% CI 2.9 to 5.1). Gel raised it 3.0% (95% CI 1.8 to 4.3), patch 1.4%, oral testosterone undecanoate 4.3% and intramuscular testosterone undecanoate 1.6%. Intramuscular enanthate or cypionate raised hematocrit significantly more than patch; the other comparisons were not significantly different [4].

Actual rates of erythrocytosis depend heavily on where the threshold is set. In one retrospective single-center review of 178 hypogonadal men followed for 3 years, hematocrit above 50% occurred in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets. The injection group was younger (mean 42.5 versus about 54 years) and had a higher baseline hematocrit, and the study was not randomized [1].

The 2025 systematic review of drug-induced erythrocytosis reports erythrocytosis rates up to 66.7% in men on prescription testosterone, with intramuscular formulations, higher doses and older age associated with increased risk [8]. A 2018 review reaches the same conclusion about formulation: short-acting injectables carry the highest incidence [9].

What the Depo-Testosterone label says

The Depo-Testosterone label for intramuscular testosterone cypionate lists polycythemia among hematologic adverse reactions and reports venous thromboembolic events, including deep vein thrombosis and pulmonary embolism, in people using testosterone products [6]. It says to check hemoglobin and hematocrit periodically during long-term use [6].

The label also says patients who report pain, edema, warmth and erythema in the lower extremity should be evaluated for deep vein thrombosis, and those who present with acute shortness of breath for pulmonary embolism, and that treatment should be discontinued if a venous thromboembolic event is suspected [6].

Does erythrocytosis raise clot risk?

It is unclear whether testosterone-related erythrocytosis leads to thromboembolic events. A 2018 review states that the link to thromboembolic events remains unclear [9], and a 2015 review calls the erythrocytosis-VTE link inconclusive [2]. The 2025 systematic review of drug-induced erythrocytosis reports thromboembolic events in up to 2.7% of men on testosterone therapy [8]. The Depo-Testosterone label notes that increased red blood cell mass may raise thromboembolic risk [6].

Options described in the literature

Changing dose or formulation. The network meta-analysis estimates a 4.0% rise in mean hematocrit with intramuscular enanthate or cypionate versus 3.0% with gel, though that pair was not significantly different [4]. The 178-man review found far lower erythrocytosis rates with gels, though its groups differed at baseline [1]. The 2025 systematic review associated higher testosterone doses with a higher risk of erythrocytosis [8].

Phlebotomy and aspirin. A review of JAK2 wild-type erythrocytosis, which is not specific to testosterone, says low-dose aspirin and/or phlebotomy (with frequency determined by symptom relief) might be considered on an individualized basis in the presence of hyperviscosity symptoms, cardiovascular comorbidities or a history of thrombosis [11].

When testosterone is not the whole explanation

Testosterone is one of several recognized causes of acquired erythrocytosis, alongside cardiopulmonary disease, renal artery stenosis, erythropoietin-producing tumors and other drugs such as SGLT2 inhibitors [12]. The first step in working up erythrocytosis is excluding polycythemia vera with JAK2 mutation screening, and relative polycythemia from volume contraction should be considered too [12][11]. Serum erythropoietin is described as variably informative [12].

Monitoring

The Depo-Testosterone label calls for periodic hemoglobin and hematocrit checks during long-term use [6]. The 2018 Endocrine Society guideline recommends monitoring hematocrit during the first year of testosterone therapy [13].